An Israeli company found the medicine for Corona patients?

by time news

Cytokine-releasing syndrome is characterized by the over-secretion of pro-inflammatory cytokines and develops in about 41% to 78% of cancer patients treated with drugs to activate the immune system against cancer (immunotherapeutic treatments). In addition, this syndrome develops, at similar rates, in patients with hematopoietic stem cell transplantation (“HSCT”), which are mainly used to replace lines of cells infected with leukemia. About 13% to 27% of patients suffering from cytokine release syndrome as a result of the treatments, will develop a multi-system failure and reach a difficult or life-threatening condition.

More in-

In contrast to non-goal-directed chemotherapy, targeted immunotherapy treatments are designed to attack only the cancer cells, and therefore their development is currently leading the study of the treatment of cancer patients. This fact, reflected in the last decade in an average annual increase of about 38% in the number of new clinical trials in CAR-T or BiTEs-based products alone, is the efficacy of the drug zencure in the treatment of cytokine release syndrome, demonstrated in The Jackson Laboratory, USA. “B, one of the most esteemed research institutes in the world.

You may also like

Leave a Comment